Table 1.
Study characteristics of included articles (n=32 articles).
| Author, Year | Country | Area of research | Type of research | Type of funding | Patient engagement specific funding |
|---|---|---|---|---|---|
| Rheault et al. [18] | United Kingdom | Alport syndrome | In vitro, In vivo | A, F | N/R |
| van den Berg et al. [19] | Netherlands | Amyotrophic lateral sclerosis (ALS) | In vitro, In vivo | G, F, I | N/R |
| Boenink et al. [20] | Netherlands | Advanced stage cancer and rheumatoid arthritis | In vitro | G | Explicit statement of funding received to support patient engagement |
| Russell et al. [21] | United Kingdom | Autism | In vivo | G, F, I | N/R |
| Tamagnini et al. [22] | United Kingdom | Alzheimer's and dementia | In vivo, Ethics of animal research | F | Explicit statement of funding received to support patient engagement |
| Frazier et al. [23] | United States | Autism | N/R | N/R | |
| Talebizadeh et al. [24] | United States | Genetics | N/R | G | No explicit statement, but the grant name suggests it may be to support patient engagement |
| McDonnell et al. [25] | United Kingdom | Lupus and antiphospholipid syndrome | N/R | G, A, F | N/R |
| Parsons et al. [26] | United Kingdom | Various arthritis diseases and bone disease | N/R | A, F | No explicit statement, but the grant name suggests it may be to support patient engagement |
| Zoeller [27] | Germany | Osteoarthritis | In vivo | N/R | |
| Filocamo et al. [28] | Italy | Rare diseases | In vitro | G, F | N/R |
| Black and Brockway-Lunardi [29] | United States | Melanoma | In vitro, In vivo | N/R | |
| Godard et al. [30] | Canada | Genetics | N/R | G | N/R |
| Author, Year | Country | Area of research | Type of research | Type of funding | Patient engagement specific funding |
| *Haga et al. [31] | United States | Genetics | In vitro | G | N/R |
| *O'Daniel et al. [32] | United States | Genetics | In vitro | G | No explicit statement, but the grant name suggests it may be to support patient engagement |
| Terry et al. [33] | United States | Genetics | In vitro | A | Explicit statement of funding received to support patient engagement |
| Pulver et al. [34] | United Kingdom | Animal models for biomedical research | In vivo | G, F | N/R |
| Arturi [35] | United States | Diamond Blackfan Anemia | In vitro | N/R | |
| Baart and Abma [36] | Netherlands | Psychiatric genomics | N/R | N/R | |
| Boon and Broekgaarden [37] | Netherlands | Neuromuscular disorders | In vitro, In vivo | N/R | |
| Van Olphen et al.[38] | United States | Breast cancer | In vivo | G | Explicit statement of funding received to support patient engagement |
| Haddow et al. [39] | United Kingdom | Genetics | In vitro | N/R | |
| Riter and Weiss [40] | United States | Cancer | N/R | G, A | N/R |
| de Wit et al. [41] | Netherlands | Rheumatic conditions | N/R | N/R | |
| Mollan et al. [42] | United Kingdom | Idiopathic intracranial hypertension | N/R | G, F | Explicit statement of funding received to support patient engagement |
| Costello and Dorris [43] | Ireland | Rheumatic conditions | In vitro, In vivo | N/R | |
| Arthritis Research UK, N/R [44] | United Kingdom | Rheumatic conditions | N/R | N/R | |
| Author, Year | Country | Area of research | Type of research | Type of funding | Patient engagement specific funding |
| Davies et al. [45] | United Kingdom | Genetics | In vivo | F | No explicit statement, but the grant name suggests it may be to support patient engagement |
| Taruscio et al. [46] | Italy | Rare diseases | N/R | N/R | |
| Moore et al. [47] | United Kingdom | Multiple sclerosis | In vitro | F | N/R |
| Mahler and Besser [48] | Germany | Stem cells | In vitro | N/R | |
| Birch et al. [49] | United Kingdom | Rheumatoid arthritis | N/R | G, A, F | N/R |
Abbreviations: A = Academic, F = Foundation/Charity, G = Government, I = Industry, N/R = Not reported
⁎
Denotes articles describing the same study.